1. Home
  2. TCBS vs VERU Comparison

TCBS vs VERU Comparison

Compare TCBS & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Texas Community Bancshares Inc.

TCBS

Texas Community Bancshares Inc.

HOLD

Current Price

$17.51

Market Cap

45.0M

Sector

Finance

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.29

Market Cap

36.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCBS
VERU
Founded
1934
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.0M
36.4M
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
TCBS
VERU
Price
$17.51
$2.29
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
1.9K
43.9K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
1.14%
N/A
EPS Growth
327.27
N/A
EPS
1.00
N/A
Revenue
N/A
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$17.51
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.01
$0.36
52 Week High
$20.00
$4.59

Technical Indicators

Market Signals
Indicator
TCBS
VERU
Relative Strength Index (RSI) 55.03 46.60
Support Level $15.48 $2.15
Resistance Level $18.05 $2.70
Average True Range (ATR) 0.35 0.11
MACD 0.10 -0.00
Stochastic Oscillator 54.68 56.10

Price Performance

Historical Comparison
TCBS
VERU

About TCBS Texas Community Bancshares Inc.

Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans and commercial real estate loans and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer and other.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: